** Customer Service Lines: For Enquiries call 0700-1-NAFDAC (0700-1-623322), For Complaints call 0800-1-NAFDAC (0800-1-6 ** Customer Service Lines: For Enquiries call 0700-1-NAFDAC (0700-1-623322), For Complaints call 0800-1-NAFDAC (0800-1-6 ** Customer Service Lines: For Enquiries call 0700-1-NAFDAC (0700-1-623322), For Complaints call 0800-1-NAFDAC (0800-1-6
** Customer Service Lines: For Enquiries call 0700-1-NAFDAC (0700-1-623322), For Complaints call 0800-1-NAFDAC (0800-1-6 ** Customer Service Lines: For Enquiries call 0700-1-NAFDAC (0700-1-623322), For Complaints call 0800-1-NAFDAC (0800-1-6 ** Customer Service Lines: For Enquiries call 0700-1-NAFDAC (0700-1-623322), For Complaints call 0800-1-NAFDAC (0800-1-6

Pharmacovigilance Newsletter

The PV/PMS Directorate sends out quarterly newsletters to stakeholders. The objectives of the newsletters are to:

  • Disseminate information on pharmacovigilance activities nationally and globally
  • Educate stakeholders on medicines safety issues
  • Promote rational use of medicines and
  • Promote spontaneous reporting of Adverse Drug Reactions(ADRs)

The newsletters are circulated to stakeholders via email. They can also be accessed below.

Contact us via fdic@nafdac.gov.ng if you would like the Newsletters delivered directly to your mail.

TitleVolumeYear Published
Antibiotic Resistance And PharmacovigilanceVol. 7 No. 22014
Introducing The PVG/FDIC NewsletterVol. 1 No. 1
Summary Of ADR On The NPC Database (Special Attention On Antibiotics)Vol. 1 No. 3
Description Of AdRs Received By The NPC That Were Due To AnalgesicsVol. 1 No. 4
Zonal Training Workshop For Institutional Drug Safety Monitoring OfficersVol. 2
Pharmacovigilance Of Antiretroviral MedicinesVol. 3 No. 3
Pharmacovigilance Of Antihypertensive MedicinesVol. 4 No. 1
Pharmacovigilance And The Use Of AntibioticsVol. 4 No. 3
Stevens Johnson SyndromeVol. 5 No. 22011
Pharmacovigilance Of Act AntimalarialsVol. 5 No. 32011
National Pharmacovigilance PolicyVol. 6 No. 12013
Pharmacovigilance Of VaccinesVol. 6 No. 22013
Overview Of Tuberculosis Infection And DiseaseVol. 7 No. 12014
Pharmacovigilance in Public Health Programmes NewsletterVol. 15 No. 22023
Pharmacovigilance Of Antidiabetic DrugsVol. 7 No. 32014
Rational Use Of MedicinesVol. 8, No. 12015
Review of Pediatric PharmacovigilanceVol. 92016
Sulfadoxine/Pyrimethamine and Stevens-Johnson SyndromeVol. 11 No. 12018
Activities At The National Pharmacovigilance Center In The Year 2018Vol. 12 No. 12019
Circulation of falsified antimalaria and antibiotics in subsaharan AfricaVol. 12 No. 22019
Fluoroquinolones and risk of disabling and potentially irreversible side effectsVol. 13 No. 12020
Regulation And Control Of Medical Product In A PandemicVol. 13 No. 22020
Pharmacovigilance A View Of Medical DevicesVol. 13 No. 32020
New Developments And Activities Of The National Pharmacovigilance Centre In The Year 2020 And 2021Vol. 14 No. 22021
Recent Developments in Nigerian Implementation of Good Distribution Practices of Pharmaceutical ProductsVol. 15 No. 12022

Was this helpful?

Yes
No
Thanks for your feedback!

More Actions